Uwell Biopharma, Inc. (TPEX:7902)
Taiwan · Delayed Price · Currency is TWD 34.15
-1.65 (-4.61%)
At close: Aug 18, 2026
Uwell Biopharma Revenue
In the year 2025, Uwell Biopharma had annual revenue of 35.00K TWD, down -92.22%. Uwell Biopharma had revenue of 35.00K in the half year ending December 31, 2025.
Revenue
35.00K
Revenue Growth
-92.22%
P/S Ratio
195,142.86
Revenue / Employee
n/a
Employees
n/a
Market Cap
6.83B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 35.00K | -415.00K | -92.22% |
| Dec 31, 2024 | 450.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Genomics BioSci & Tech. | 718.16M |
| HanchorBio | 312.22M |
| Pet Pharm Biotech | 265.54M |
| BIONET Therapeutics | 196.63M |
| Elixiron Immunotherapeutics (Cayman) Limited | 113.34M |
| TLC BioSciences | 89.44M |
| Intelligene | 796.00K |